The agency announced a 17-month, $12.7 million agreement under which Emergent BioSolutions will develop an intranasal, stabilized form of isoamyl nitrite. Sep 19, 2017 The first nose spray treatment ...
Emergent BioSolutions said today it won an approximately $63 million contract from the Biomedical Advanced Research and Development Authority (BARDA) toward developing an antidote spray device for ...
Emergent BioSolutions Inc. EBS announced the initiation of dosing in its phase I study, which is evaluating its pipeline candidate, stabilized isoamyl nitrite (“SIAN”), for treating known or suspected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback